Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 vs TCbHP in Neoadjuvant HER2+ Breast Cancer
NCT07136974Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in breast cancer, sponsored by Henan Cancer Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07136974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136974.